🇺🇸

US SEC Filing Intelligence

· daily

US Executive Officer Management Changes SEC — May 12, 2026

Across 50 filings in the USA Executive & Director Changes stream (43 new), the dominant theme is routine annual shareholder meetings (20+ companies) approving directors, equity incentive plans (share increases averaging 4-6M shares), say-on-pay, and auditors with strong majorities, signaling stable governance amid minor oppositions (e.g., 20% against Piedmont's plan). Executive transitions dominate (25+ cases), mostly neutral/positive retirements/appointments (e.g., new COOs/CFOs/CEOs at Standard Motor, Laser Photonics, Eagle Bancorp) with seamless handovers, though negative separations (HF Sinclair CEO/CFO) and distress (Bitcoin Depot) stand out. Period trends show robust revenue growth in growth sectors (SOLV +66% YoY Q1 rev/$93M EBITDA +174%; Arteris +39% YoY; Nextpower FY26 +20% to $3.56B; TransAct +10% YoY) but widening losses (C3.ai FY26 op loss $(217.8)M vs $(88.1)M; Bitcoin -49% YoY rev). Capital allocation favors repurchases (Progressive 25M shares, TransAct $3M) and dividends (Progressive $0.10/share July 10), while M&A (SOLV $45M acquisition) and financings (Achieve $354M) support growth. Forward-looking catalysts include FDA dates (Achieve June 20), retirements (Arteris CFO Aug 31), and guidance raises (SOLV EBITDA $435-455M FY26), implying portfolio-level stability but sector-specific alpha in tech/energy transitions.

50 high priority 50 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 12, 2026

Across 50 SEC filings on USA Board Room Changes from May 12, 2026, dominant themes include orderly executive transitions (12 CEO/CFO changes, mostly retirements/appointments with successors), annual shareholder meetings (20+ with director elections and equity plan approvals, averaging 90%+ support but 20% opposition on share increases), and board expansions with industry veterans (e.g., ex-TI, Caterpillar execs). Period-over-period trends show revenue acceleration in 7 reporters (avg +37% YoY: SOLV +66%, Arteris +39%, Nextpower +20%), but mixed profitability (SOLV EBITDA +174%, yet net losses widened in HF Sinclair, Bitcoin Depot -49% YoY rev). Guidance raised in SOLV ($435-455M EBITDA), Arteris ($91-95M rev), TransAct ($1-1.75M EBITDA), signaling growth conviction amid transitions. Capital allocation favors buybacks (TransAct $3M, Progressive 25M shares) and dividends (Progressive $0.10/share). Portfolio-level patterns: Financials/healthcare see high turnover (8 changes), tech/energy mixed financials with positive board sentiment (avg materiality 7/10). Implications: Bullish stability in most changes boosts confidence; monitor financial reporters for Q2 catalysts amid 5 negative departures.

50 high priority 50 total filings
· daily

US Merger & Acquisition SEC Filings — May 12, 2026

The 12 filings reveal a surge in US M&A and divestiture activity, with 7/12 involving asset sales, acquisitions, or JVs totaling over $5B in value, including Plains' $3.3B Canadian NGL divestiture and Collegium's $650M AZSTARYS buyout, signaling portfolio optimization and strategic refocusing amid mixed economic signals. Period-over-period trends show revenue declines in divestitures (e.g., Ashford -0.6% pro forma YoY to $1.1B) offset by loss improvements (Ashford net loss -4% to $181M, Mereo Q1 loss -48% YoY to $6.7M), while guidance upgrades (Collegium +8% revenue to $865-895M) highlight accretive deals. SPACs dominate extensions (4/5 filings), buying time for deals with neutral-to-positive sentiment. Energy midstream firms like Plains target 3.25-3.75x leverage post-sale for durable FCF, contrasting pharma's mixed clinical outcomes (Mereo Phase 3 misses primary but hits secondary endpoints). Overall, bullish on deleveraging and growth via M&A, but watch SPAC liquidity risks and clinical/regulatory hurdles; portfolio-level theme is crude oil focus and ADHD pharma expansion.

12 high priority 12 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 12, 2026

Overnight SEC filings for May 11-12, 2026, are dominated by 37 13F-HR reports revealing strong institutional conviction in mega-cap tech (Apple, NVIDIA, Amazon topping 20+ portfolios, avg 20-40% allocation), signaling sustained bullishness on AI/semiconductors amid no reported changes from Q1 2026. Earnings releases show mixed Q1 2026 results: 5/7 reporting companies achieved revenue growth averaging +11% YoY (Ducommun +9%, Qnity +18%, Green Dot +17%), but margins varied (+70bps Ducommun to compressions elsewhere) and losses widened in high-growth names like BETA (+5.6% rev but -56% net income YoY). Guidance trends positive with raises (Qnity FY sales $5.225-5.375B, Optex FY rev $43-45M up from $41.3M), offset by widened loss outlooks (BETA Adj EBITDA -$355-445M). Capital raises prominent (IREN $2.6B notes due 2033, UGI €300M notes), exec transitions neutral-to-positive (Diodes new Chair, Astrana CMO resignation), and risks in compliance (Maison Nasdaq violation). Sector themes highlight aero/defense resilience, electronics outperformance, and heavy foreign investor tech bets; actionable now: buy electronic/aero dips pre-catalysts, monitor tech overweight for rotation risks.

6 high priority 44 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 11, 2026

The May 11, 2026 period recorded 1 Other approval in the biotech small-cap stream: ZHEJIANG NOVUS's VORICONAZOLE under FALLBACK type, categorized as 0 NMEs, 0 biosimilars, 0 label expansions, and 1 Other. This single event carries a neutral signal (strength 5/10, materiality 5/10) with no dominant therapeutic area theme evident. The highest-conviction signal is ZHEJIANG NOVUS's VORICONAZOLE approval, a biosimilar entry with fully NOT_DISCLOSED commercial metrics including peak sales, exclusivity, and pricing power. Balanced upside exists for the entrant via potential market access, offset by execution risks in a mature antifungal space. Key risk/watch item is ZHEJIANG NOVUS launch dynamics and competitive positioning given limited disclosed details.

1 total filings
· daily

New Drug Approvals (Original) — May 11, 2026

The May 11, 2026 period saw 1 FDA approval categorized as Other (0 NMEs, 0 biosimilars, 0 label expansions), consisting solely of ZHEJIANG NOVUS's VORICONAZOLE biosimilar approval with a neutral signal (strength 5/10, materiality 5/10). No dominant therapeutic area theme emerges from this single approval. The highest-conviction signal is the neutral commercial implication for ZHEJIANG NOVUS's entry into the VORICONAZOLE market, representing a fallback approval with no disclosed peak sales, exclusivity, or pricing data. This dual-edged event is bullish for the new entrant ZHEJIANG NOVUS but bearish for the VORICONAZOLE originator due to potential revenue erosion. Key risk/watch item is competitive pressure on the originator's market position post-launch.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 11, 2026

Across 38 diverse SEC filings dominated by institutional 13F-HR disclosures, a clear portfolio-level pattern emerges of unwavering conviction in S&P 500 Technology mega-caps, with 12+ institutions reporting unchanged top holdings in Apple ($100M+ positions across NLB, MUFG EMEA, Elo, Nomura), Broadcom ($70M+ in NLB, $308M MUFG EMEA), Alphabet, Amazon, and Nvidia amid Q1 2026 portfolio stability. Period-over-period trends show mixed revenue performance outside tech: declines averaging -10% YoY in media (Townsquare -1.9%), semis (Sequans -29%), and logistics nine-month (Radiant -1.4%), offset by pockets of resilience like digital ad growth (+6.9% Townsquare) and hotel rev surges (+35% Portsmouth). Capital allocation favors dividends (Townsquare $0.20, Esquire $0.20 up from $0.175, Mueller $0.35), buybacks (Radiant $3.5M), while biotechs face cash burn (MoonLake -72% net loss YoY, runway to 2027). Forward-looking catalysts cluster in biotech (MoonLake BLA Sep 2026) and media guidance reaffirmations, but liquidation (Elme assets -72% QoQ) and going concern doubts (Planet Green) signal distress in non-core holdings. Implications: Bullish tech overweight via institutions supports sector rotation; selective opportunities in guided growth names amid broader small-cap weakness.

12 high priority 26 medium 38 total filings
· daily

Nasdaq 100 Stocks SEC Filings — May 11, 2026

Across 37 filings from NASDAQ-100 related entities on May 11, 2026, dominant themes include positive biotech catalysts (e.g., MoonLake, Intellia advancing BLAs), institutional stability with unchanged heavy tech allocations in 13Fs (Apple, Alphabet topping multiple portfolios), mixed quarterly results showing loss narrowing in small caps like Radiant Logistics (+88% net income YoY) and biotechs despite revenue dips, and ongoing liquidations/debt issuances signaling capital maneuvers. Period-over-period trends reveal 6/12 operational filings with YoY net loss improvements (avg +45% narrowing, e.g., Intellia -16%, Radiant +88%), but revenue stagnation/declines in logistics (Radiant flat) and semis/comms (Sequans -29%). Capital allocation leans toward buybacks (Radiant $3.5M), dividends (Mueller $0.35/share), and debt raises (Alphabet €9B, Booking €1.9B) for growth funding. Biotech forward-looking dominates with 4 BLA/PDUFA catalysts H2 2026-H1 2027, while Elme's liquidation eyes mid-2026 completion with $431M proceeds. Portfolio implications favor biotech alpha amid tech overweight stability, but flag cash burns and liquidation risks.

14 high priority 23 medium 37 total filings
· daily

S&P 500 Financials Sector SEC Filings — May 11, 2026

Across 50 SEC filings in the USA S&P 500 Financials stream dated May 11, 2026, mixed sentiment prevails in 25+ cases, with revenue growth averaging +20-30% YoY in high performers (e.g., NESR +33.5%, Gold.com +244%) offset by declines in 10+ firms (e.g., Townsquare -1.9%, Udemy -4%) and margin compressions (e.g., Dole EBITDA -4.3%). Financials-specific trends show banks expanding via M&A (Prosperity assets +13% QoQ to $43.6B, Western Alliance deposits +7.2%), BDCs with income gains but NAV pressure (Carlyle +16.8% investment income, -2.2% NAV), and 13Fs signaling conviction (MUFG $62B Morgan Stanley stake, Easterly Jackson Financial $22M). Capital allocation is robust with 12+ firms advancing dividends/buybacks (NESR new $0.10/share div + $50M repurchase, Prosperity $57M buybacks). Forward-looking data includes 5 guidance reaffirms/raises (Kodiak FY EBITDA $820-860M, Townsquare $420-440M rev) and catalysts like earnings calls on May 11. Portfolio-level patterns highlight M&A-driven growth in financial services, uneven Q1 profitability, and institutional flows into financial names amid volatility, favoring selective longs in capital-returning growers.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — May 11, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors like energy, biotech, and finance), mixed sentiment prevails with 12/20 high-materiality operational filings showing revenue growth (avg +35% YoY where positive, e.g., CleanCore +113%, Kodiak +6.2%) offset by widespread net losses or margin compression (e.g., HAIN -13% sales, OPAL -14% rev). Period-over-period trends reveal portfolio-level margin deterioration averaging -100bps in 6/10 reporting firms amid rising G&A (e.g., CleanCore +1350% YoY) and impairments, but capital allocation shines with debt reductions (ARKO -50% total debt QoQ, HAIN -$155M), buybacks/tenders (FS KKR $450M program), and reaffirmed/raised guidance (Kodiak EBITDA to $820-860M). Biotech and energy outliers like MoonLake/Intellia (BLA catalysts H2 2026) and Constellation (+1247% NI YoY) signal resilience, while 25+ 13F-HRs indicate steady institutional conviction in tech/ETFs (e.g., Apple, NVIDIA top holdings). Key implications: Favor debt deleveragers and guidance raisers for near-term alpha; monitor liquidation risks (Elme) and crypto volatility (CleanCore -$107M digital loss). Overarching theme: Defensive staples under pressure, but M&A/capex in adjacents (Calpine acquisition) drives upside.

11 high priority 39 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — May 11, 2026

Across 50 SEC filings from S&P 500 Industrials and related sectors dated May 11, 2026, Q1 2026 earnings reveal mixed results with 8/12 reporting companies showing strong revenue growth averaging 32% YoY (e.g., Babcock & Wilcox +44%, Village Farms +27%) but widened net losses in 7/12 due to non-cash charges, merger costs, and expense inflation (avg net margin deterioration -300 bps). Restructuring themes dominate via spin-offs (Resideo's ADI Global at $4.8B rev), M&A proposals (Dream Finders for Beazer Homes), and leadership shuffles (Faraday Future, SolarEdge CFO), signaling value unlocks amid operational shifts. Defense/aerospace wins like Red Cat's $9.5M Army drone order contrast profitability pressures in hospitality (Target Hospitality EBITDA -54% YoY) and tech-adjacent (Udemy rev -4%). Capital returns remain robust with $200M+ aggregate buybacks/dividends in Q1 (e.g., Western Alliance $50M repurchases, Prosperity $57M). Institutional 13F filings (18/50) show steady mega-cap tech overweight (Apple, Alphabet top across portfolios) with minimal industrials shifts, implying defensive positioning. Forward catalysts cluster in H2 2026: spin-offs mid-Q3/Q4, investor days July, Phase 3 trials. Overall, tactical opportunities in contract wins and spin-offs outweigh broad margin risks, favoring selective longs in high-backlog names.

17 high priority 33 medium 50 total filings
· daily

US Material Events SEC 8-K Filings — May 11, 2026

Across 50 SEC filings from May 11, 2026, the dominant theme is extensive executive churn with 20+ resignations (mostly neutral, no disagreements) and 15+ appointments/promotions, signaling potential leadership stabilization or transitions in tech, finance, and industrials amid a stabilizing market. SPAC activity surges with 3 new IPOs priced at $100M each (Shreya, Vernal), alongside M&A like Apollo's $1.5B Emerald acquisition at 42% premium and Resideo's Q3/Q4 ADI spin-off unlocking $4.8B revenue segment. Financial results are mixed: Cronos +40% YoY revenue standout vs FSK/ZoomInfo declines (NAV -10% QoQ, guidance cut 5%), with aggregate revenue growth in reporting firms averaging +20% YoY but margins compressing -1-2pp in 3/5 cases. Capital allocation leans shareholder-friendly: $300M FSK buyback/tender, Cronos $50M repurchase renewal, multiple financings ($450M Credit Acceptance, $725M McGrath). No widespread insider trading data, but positive guidance in Faraday (1,000 robots 2026) and strong annual meeting approvals (UPS, Alcoa) point to resilient governance. Portfolio-level, finance/BDCs show stress (higher debt ratios), while SPACs/healthcare offer entry points; watch Q2 catalysts like FSK tender (May 12) and Resideo investor day (mid-July). Overall, actionable now: favor spin-offs/M&A over pure earnings reporters.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — May 11, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (May 11, 2026 period), mixed sentiment dominates with 70% of operating companies (e.g., NESR, Kodiak, B&W) reporting YoY revenue growth averaging +25% in Q1 2026, driven by energy/services and acquisitions, but profitability challenged by one-time costs, margin compression (avg -50bps in 8/15 reporters), and rising provisions (e.g., Western Alliance +583% YoY). Capital allocation trends positive with new dividends (NESR $0.10/share Q4 2026 start, ARKO $2.00 annual), buybacks ($50M NESR, $57M Prosperity), and debt reductions (ARKO -50% QoQ, B&W net debt $42.4M). Forward guidance largely raised/affirmed (Kodiak EBITDA $820-860M, eXp FY rev $4.85-5.15B), signaling resilience amid M&A activity (Sonida $1.8B CHP, Olaplex $1.4B Henkel). Institutional 13Fs (11 filings) show heavy tech concentration (Apple, NVDA, MSFT top holdings across $20B+ AUM), indicating conviction in mega-caps. Key themes: energy rebound, banking consolidation, biotech catalysts; actionable now: buy growth outliers pre-earnings, monitor merger risks.

17 high priority 33 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — May 11, 2026

Across 50 SEC filings for May 11, 2026, a dominant theme is mixed financial performance with robust revenue growth in energy services (e.g., NESR +33.5% YoY, Kodiak +6.2% YoY) contrasting weakness in media/advertising (Townsquare -1.9% YoY) and select tech/consumer segments, amid 11.6% YoY revenue gains at Dole but EBITDA declines. Period-over-period trends show 18/25 quarterly reporters with YoY revenue growth averaging +25% in energy/oil vs. -5% in media, though margins compressed in 12 companies (avg -100 bps) due to impairments/expenses; net income swings positive in 10 firms via tax benefits or cost controls. Capital allocation leans shareholder-friendly with dividends/buybacks in 9 firms (e.g., NESR $0.10/share dividend + $50M repurchase), while forward-looking guidance raised in 5 (Kodiak EBITDA to $820-860M, Seadrill revenues $1.43-1.48B). Institutional 13Fs reveal concentrated bets on STAA, LU, API; IPO/SPAC momentum with EagleRock's Permian surge (308% YoY rev) and Shreya's $100M pricing signals M&A/expansion alpha. Portfolio-level, energy outperforms (avg +40% YoY EBITDA in 4 firms) vs. BDCs/REITs lagging; watch Q2 catalysts like NESR dividends and Kodiak power capacity adds for rotational trades.

29 high priority 21 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — May 11, 2026

Across 50 filings from S&P 500 Consumer Discretionary and related sectors, Q1 2026 results show mixed revenue trends with 6/12 quarterly reporters posting YoY declines averaging -19% (e.g., OPAL Fuels -14%, bioAffinity -27%, Bitfarms -22%), offset by outperformers like Village Farms +27% sales and Target Hospitality +4% revenue, amid widespread margin compression and net losses in 7/12 cases. Leadership transitions dominate positive narratives (Faraday Future founder CEO return, SolarEdge CFO appoint, Atmus SVP), signaling strategic resets, while M&A activity surges with Dream Finders' Beazer bid, Flag Ship LOI, and Odyssey merger risks. Capital allocation leans supportive with FS KKR's $150M tender/$300M buyback, Village Farms $6.4M repurchases, and Ellington $0.13 monthly dividend, but cash burns and going concern doubts (Perma-Fix, bioAffinity) flag liquidity strains. Institutional 13Fs (13/50 filings) reveal stable mega-cap tech overweight (Apple, Alphabet top across MUFG, Knights of Columbus, etc.), implying conviction in consumer tech proxies. Forward guidance mixed but intact (Target $370-380M FY rev, OPAL maintains FY), building a catalyst-rich calendar amid EV/robotics growth (Faraday 68 robots shipped, +gross margins). Portfolio implication: Selective opportunities in turnarounds with contracts/guidance, avoid high-burn losers; sector faces utilization drops (Target beds 54% vs 60%) but AI/infra tailwinds emerging.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — May 11, 2026

Across 50 filings in the S&P 500 Healthcare stream, 13F-HR reports dominate (over 60%), revealing institutional portfolios overwhelmingly tilted to tech megacaps (Apple, MSFT, NVDA topping 25+ filers, e.g., $709M Apple in Cincinnati Financial) with secondary but stable healthcare exposure (AbbVie $270B Citigroup, $305M Cincinnati Insurance, Lilly $7M CIGNA). Healthcare-specific filings highlight biotech momentum with positive clinical data (Inhibrx Phase 2 ORR 44% vs 21% control +24% edge, MBX Biosciences 7% weight loss Phase 1) contrasting small-cap deterioration (Elicio Q1 loss widened to $11.8M +5% YoY, BioScience rev -38.8% YoY to $0.75M). Adjacent financials show resilient NII growth averaging +12% YoY (Esquire +23%, C&F +11%, Flushing swing to $5.8M profit) amid rising provisions (+20-100%). Capital allocation leans shareholder-friendly (Ellington monthly $0.13 dividend June 30, News Corp $1B buyback ongoing, Flushing dividend doubled to $0.44), but dilution risks loom (ACRES ~105% share issuance vote). Forward catalysts cluster Q3-Q4 2026 (Inhibrx Phase 3/PFS, MBX 12-wk data); neutral-to-mixed sentiment prevails with no notable insider trading patterns. Portfolio implication: tactical biotech alpha amid broad market tech rotation, monitor dilution votes.

11 high priority 39 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — May 11, 2026

Across 14 DEF 14A proxy statements dated around May 11, 2026, overarching themes include routine director elections, say-on-pay advisory votes, and auditor ratifications, but with standout strategic actions: significant dilution from ACRES' internalization merger (105% dilution via 7.5M new shares), Coursera's Udemy merger boosting scale to $1.5B revenue, Jushi's domestication to Nevada, and reverse consolidations in OFA (1:10) and Revelation (up to 1:250). Period-over-period data is sparse but reveals Coursera's robust 9% YoY revenue growth to $757.5M and record $78.5M FCF, contrasting OFA's executive comp surges (CEO +1,865% YoY to $724K, CTO +483% to $215K) as the sole quantified pay trend amid multi-year comp tables in DBV, Navitas, Pulse, and others showing no declines noted. No insider trading activity reported across filings, but high insider voting control in OFA (98.68%) raises governance flags. Forward-looking catalysts cluster in June 2026 annual meetings (June 3-DBV to June 25-Navitas/Blue Dolphin), potentially impacting share structures and governance. Portfolio-level patterns show neutral sentiment dominating (10/14), with positive outliers in growth/edtech (Coursera, OFA) and mixed risks in realty/biotech dilution plays; implications favor monitoring vote outcomes for near-term volatility in small-caps.

14 high priority 14 total filings
· daily

US IPO Pipeline SEC S-1 Filings — May 11, 2026

The IPO Pipeline stream reveals a surge in S-1 filings for traditional IPOs and direct listings (WhiteHawk, Virtuix, Neptune, Sunshine Silver, INNIO, AParadise), alongside S-4s for mergers and business combinations (Odyssey, Public Storage, MicroTouch), signaling robust US SEC activity on May 11, 2026, with 7 new filings emphasizing emerging growth and controlled companies. Key period-over-period trends include standout 47% YoY revenue growth and net income turnaround to positive $4.4M in WhiteHawk's Q1 2025 energy sales, contrasted by mixed executive compensation shifts in Virtuix (CEO +79% to $448K, President -25%) and stable SPAC finances in AParadise. Merger proposals dominate with scale opportunities (Public Storage-NSA combining 4,237 facilities) but highlight fixed exchange ratios, termination fees up to $2.2M, and operational restrictions. Portfolio-level patterns show 5/9 filings as controlled companies post-IPO (Neptune CEO 84%, Sunshine Electrum, INNIO AI Alpine), reducing governance standards, while energy/mining (WhiteHawk, Sunshine) outperforms with positive/marginal sentiment vs negative merger risks. Capital allocation leans toward repurchases (Neptune 836K shares) over dividends/buybacks elsewhere. Market implications favor monitoring IPO catalysts amid merger risks, with energy names as relative outperformers.

9 high priority 9 total filings
· daily

Global High-Priority Regulatory Events — May 11, 2026

The 50 filings reveal a surge in Indian insolvency resolutions and neutral SEBI regulatory confirmations (not Large Corporates) across 15+ companies, signaling compliance but low operational impact, alongside high-materiality US events like SPAC IPOs, M&A updates, and mixed Q1 2026 10-Qs. Aggregate period trends show revenue growth in 12/25 US filers averaging +25% YoY (e.g., NESR +33.5%, Dole +11.6%, Gold.com +244%), but 14 reported widening losses or impairments due to non-cash charges, margin compression (avg -150bps in media/tech), and high debt; banks like Prosperity (+13% assets) and Western Alliance (+6.5% assets) expanded via M&A/deposits. Insolvencies dominate critical events: Morarjee Textiles plan orally approved (positive), SKIL Infrastructure critically weak (negative). Capital allocation leans shareholder-friendly with dividends/buybacks in 8 firms (e.g., Carlyle $28M divs +$18M repurchases), but cash burns persist in biotech/energy. SPACs raised $300M+ (Shreya $100M, Quantum Leap $200M), flagging M&A catalysts. Portfolio implication: Opportunistic buys in turnaround energy/produce amid volatility; avoid distressed insolvencies without resolution catalysts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 11, 2026

Across 50 Q1 2026 10-Q and 10-K filings, results are predominantly mixed, with 28/50 companies (56%) reporting YoY revenue growth averaging +35% in outperformers like NESR (+33.5%), Gold.com (+244%), and Liquidia (from $3K to $133K), but declines in 22/50 averaging -10% in media (Townsquare -1.9%), renewables (OPAL -14%), and crypto/mining (Bitfarms -22%). Profitability trends show 24/50 achieving net income improvements or turns to profit (e.g., RingCentral from loss to $31M), but 26/50 widened losses amid rising expenses, impairments, and unrealized losses in BDCs (FS KKR net decrease $441M vs +$120M YoY). Capital allocation remains shareholder-friendly with 18/50 announcing buybacks (e.g., Western Alliance $50M, Certara $40M) and 15/50 dividends (e.g., Carlyle $28M up YoY), signaling conviction despite macro pressures. Banks shine with asset growth (e.g., Prosperity +13% QoQ to $43.6B via M&A), while biotech/pharma burns cash on R&D (avg +30% YoY). M&A activity (Prosperity, Gold.com, Constellation Calpine $20B+ equiv) and financing inflows bolster balance sheets in 20/50, but going concern doubts (EchoStar) and high debt (Apollo Debt +11% QoQ) flag risks. Portfolio implication: overweight banks/energy, underweight volatile renewables/BDCs ahead of rate cuts.

50 high priority 50 total filings